Taysha Gene Therapies (TSHA) Capital Expenditures (2020 - 2026)
Taysha Gene Therapies (TSHA) reported Capital Expenditures of $24000.0 for Q1 2026, up 4.35% on a YoY basis from $23000.0 in Q1 2025, and down 96.63% sequentially from $713000.0 in Q4 2025.
Taysha Gene Therapies (TSHA) Capital Expenditures (2020 - 2026) Analysis & Trends
Taysha Gene Therapies (TSHA) has 7 years of Capital Expenditures data on file, last reported at $24000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures rose 4.35% year-over-year to $24000.0; the trailing twelve-month figure through Mar 2026 stood at $739000.0 (up 187.55% YoY), and the FY2025 full-year result was $738000.0, up 97.33% from the prior year.
- Capital Expenditures eased to $24000.0 in Q1 2026, from $713000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $20.6 million in Q4 2022 to a low of -$3.4 million in Q3 2023.
- A 5-year average of $1.5 million and a median of $24000.0 in 2026 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures slumped 4869.57% in 2023 and jumped 35750.0% in 2025, its largest moves.
- Tracing TSHA's Capital Expenditures over 5 years: stood at $20.6 million in 2022, then plunged by 83.25% to $3.4 million in 2023, then tumbled by 100.06% to -$2000.0 in 2024, then jumped by 35750.0% to $713000.0 in 2025, then sank by 96.63% to $24000.0 in 2026.
- Business Quant data shows TSHA's Capital Expenditures at $24000.0 in Q1 2026, $713000.0 in Q4 2025, and -$386000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Taysha Gene Therapies | 2.14 Bn | 2.14 Bn | - | 24,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24,000.00 |
| Mar 31, 2026 | 24,000.00 |
| Dec 31, 2025 | 713,000.00 |
| Dec 31, 2025 | 713,000.00 |
| Sep 30, 2025 | -386,000.00 |
| Sep 30, 2025 | -386,000.00 |
| Jun 30, 2025 | 388,000.00 |
| Jun 30, 2025 | 388,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Sep 30, 2024 | -69,000.00 |
| Sep 30, 2024 | -69,000.00 |
| Jun 30, 2024 | 305,000.00 |
| Jun 30, 2024 | 305,000.00 |
| Mar 31, 2024 | 140,000.00 |
| Mar 31, 2024 | 140,000.00 |
| Dec 31, 2023 | 3.45 Mn |
| Dec 31, 2023 | 3.45 Mn |